Latest Pharma Insights
Novartis On The Future Of CV In A World Of GLP-1s
CV, renal and metabolic R&D leaders Ruchira Glaser and Shaun Coughlin talked to Scrip about investments and catalysts in the therapeutic area.
Scrip - May 21, 2026
CV, renal and metabolic R&D leaders Ruchira Glaser and Shaun Coughlin talked to Scrip about investments and catalysts in the therapeutic area.
Scrip - May 21, 2026
Health Organizations Rebuke Kennedy For Firing USPSTF Leadership
Several public health organizations are voicing concern over the firing of two top leaders of the US Preventive Services Task Force by HHS Secretary Robert F. Kennedy Jr. Critics say the removal of John Wong and Esa Davis erodes trust in the healthcare system and threatens public health.
Medtech Insight - May 21, 2026
Several public health organizations are voicing concern over the firing of two top leaders of the US Preventive Services Task Force by HHS Secretary Robert F. Kennedy Jr. Critics say the removal of John Wong and Esa Davis erodes trust in the healthcare system and threatens public health.
Medtech Insight - May 21, 2026
Executives On The Move: Six CMOs And Four CFOs Among This Week’s Changes
Recent moves in the industry include changes at the top at Achieve Life Sciences, AstronauTx and IMMEDIATE Therapeutics, plus Johnson & Johnson gets a new Human Resources head in China.
Scrip - May 21, 2026
Recent moves in the industry include changes at the top at Achieve Life Sciences, AstronauTx and IMMEDIATE Therapeutics, plus Johnson & Johnson gets a new Human Resources head in China.
Scrip - May 21, 2026
Execs On The Move: May 11–15, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - May 21, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - May 21, 2026
GHO, CBC Combine In $21bn Deal To Form Healthcare Investment Behemoth
The pact will combine the financial firms’ complementary strengths across Asia-Pacific, North America and Europe, creating an investment manager with more than $21bn in assets.
Medtech Insight - May 21, 2026
The pact will combine the financial firms’ complementary strengths across Asia-Pacific, North America and Europe, creating an investment manager with more than $21bn in assets.
Medtech Insight - May 21, 2026
Nestlé And Dr Reddy’s Launch Supplement For India’s GLP-1 Users
Indian users of GLP-1 therapies for weight loss can now purchase a supplement developed by Nestle and Dr Reddy's to support their nutritional requirements.
HBW Insight - May 21, 2026
Indian users of GLP-1 therapies for weight loss can now purchase a supplement developed by Nestle and Dr Reddy's to support their nutritional requirements.
HBW Insight - May 21, 2026
Medtech On The Battlefield: Aristeia Takes Mechanical Tourniquet To Ukraine
The Norwegian start-up found itself in the war effort when the Ukrainian government ordered hundreds of its one-handed pull-cord tourniquets.
Medtech Insight - May 21, 2026
The Norwegian start-up found itself in the war effort when the Ukrainian government ordered hundreds of its one-handed pull-cord tourniquets.
Medtech Insight - May 21, 2026
Dr Reddy’s Adds Oral Tablets To Indian Semaglutide Offering
Dr Reddy’s has made good on recent promises to introduce its oral semaglutide generic in India.
Generics Bulletin - May 21, 2026
Dr Reddy’s has made good on recent promises to introduce its oral semaglutide generic in India.
Generics Bulletin - May 21, 2026
Boston Scientific Doubles Down On Cardiac M&A As Pacemaker Recall Escalates
Four deaths, 2,557 serious injuries and 1.4 million devices later, the company is betting a software upgrade — and a wave of cardiac acquisitions — can contain the damage.
Medtech Insight - May 21, 2026
Four deaths, 2,557 serious injuries and 1.4 million devices later, the company is betting a software upgrade — and a wave of cardiac acquisitions — can contain the damage.
Medtech Insight - May 21, 2026
Strides Tempers US FY28 Guidance As Controlled Substances Face Quota Hurdle
Strides' US controlled substances portfolio is taking time to scale, but is set to deliver in FY29. Meanwhile, a FY28 US revenue guidance of $375m-$400m has been cut from $400m earlier, though an attempt to meet the target is on.
Generics Bulletin - May 21, 2026
Strides' US controlled substances portfolio is taking time to scale, but is set to deliver in FY29. Meanwhile, a FY28 US revenue guidance of $375m-$400m has been cut from $400m earlier, though an attempt to meet the target is on.
Generics Bulletin - May 21, 2026
Health Literacy And Pharmacy Key To Improving Men’s Self-Care
A report from Global Action on Men's Health identifies health literacy and pharmacy as key levers for improving men's self-care, with implications for companies marketing OTC and consumer health products to men.
HBW Insight - May 21, 2026
A report from Global Action on Men's Health identifies health literacy and pharmacy as key levers for improving men's self-care, with implications for companies marketing OTC and consumer health products to men.
HBW Insight - May 21, 2026
BioMarin Looks To Expand Voxzogo Franchise With Positive Hypochondroplasia Data
Positive Phase III hypochondroplasia data could help BioMarin expand the Voxzogo franchise beyond achondroplasia as competition in skeletal dysplasias intensifies.
Scrip - May 21, 2026
Positive Phase III hypochondroplasia data could help BioMarin expand the Voxzogo franchise beyond achondroplasia as competition in skeletal dysplasias intensifies.
Scrip - May 21, 2026
The Wonders Of The Microbiome Approach According To Freya Biosciences
Colleen Acosta, CEO and co-founder of Freya Biosciences, focuses on the success of developing microbial immunotherapies, and why industry must direct more attention to the space of women’s healthcare.
In Vivo - May 21, 2026
Colleen Acosta, CEO and co-founder of Freya Biosciences, focuses on the success of developing microbial immunotherapies, and why industry must direct more attention to the space of women’s healthcare.
In Vivo - May 21, 2026
MedTech Forum 2026: Global Trade Is No Longer Just A Question Of Economics
In 2026, the heavy hand of geopolitics, industrial policy, economic security and resilience has dictated the pace – or even the fact of – global trade in medtech, said MedTech Europe’s Diana Kanecka on a panel at the MedTech Forum 2026.
In Vivo - May 21, 2026
In 2026, the heavy hand of geopolitics, industrial policy, economic security and resilience has dictated the pace – or even the fact of – global trade in medtech, said MedTech Europe’s Diana Kanecka on a panel at the MedTech Forum 2026.
In Vivo - May 21, 2026
The Call At MedTech Forum 2026: Bring The Medtech Innovation Launch Pad Back To Europe
MedTech Europe CEO Oliver Bisazza set out his hopes and aims for EU industry and markets during the MedTech Forum 2026 against a backdrop of cautious optimism in regulatory and strategy circles now the MDR/IVDR revision is getting EU co-legislator attention. Elsewhere, there remains work to do.
Medtech Insight - May 21, 2026
MedTech Europe CEO Oliver Bisazza set out his hopes and aims for EU industry and markets during the MedTech Forum 2026 against a backdrop of cautious optimism in regulatory and strategy circles now the MDR/IVDR revision is getting EU co-legislator attention. Elsewhere, there remains work to do.
Medtech Insight - May 21, 2026
Lilly Keeps Building Genetic Medicines Capabilities With $202m Engage Bio Buyout
Acquisition of the biotech and its non-viral DNA delivery technology adds to a string of bets across next-generation approaches in gene-based therapies.
Scrip - May 21, 2026
Acquisition of the biotech and its non-viral DNA delivery technology adds to a string of bets across next-generation approaches in gene-based therapies.
Scrip - May 21, 2026
Apixaban Tops Two Tables As UK Rises Persist In April
UK generics price rises continued in April, with apixaban rivals to Eliquis topping our Biggest Risers table while also reflecting the steepest increase among our Recent Launches.
Generics Bulletin - May 21, 2026
UK generics price rises continued in April, with apixaban rivals to Eliquis topping our Biggest Risers table while also reflecting the steepest increase among our Recent Launches.
Generics Bulletin - May 21, 2026
OneSource Adds US To Its Semaglutide Ambitions, Plans Capacity Hikes
OneSource has added the US to its geographic expansion plans for GLP-1 semaglutide and after a strong showing in India by its generics partners, it is hiking capacity for its drug-device combinations.
Generics Bulletin - May 21, 2026
OneSource has added the US to its geographic expansion plans for GLP-1 semaglutide and after a strong showing in India by its generics partners, it is hiking capacity for its drug-device combinations.
Generics Bulletin - May 21, 2026
Meloxicam Could Be Viatris’ Late Christmas Present
Viatris has secured a 27 December 2026 PDUFA date for fast-acting meloxicam, setting up a key US value-added medicines opportunity as it targets non-opioid acute pain and higher-margin growth.
Generics Bulletin - May 21, 2026
Viatris has secured a 27 December 2026 PDUFA date for fast-acting meloxicam, setting up a key US value-added medicines opportunity as it targets non-opioid acute pain and higher-margin growth.
Generics Bulletin - May 21, 2026
Gedeon Richter Wants More On GLP-1s
Hungarian player Gedeon Richter is deepening its GLP-1 push with multiple co-development talks, as its General Medicines generics unit works through a difficult first quarter.
Generics Bulletin - May 21, 2026
Hungarian player Gedeon Richter is deepening its GLP-1 push with multiple co-development talks, as its General Medicines generics unit works through a difficult first quarter.
Generics Bulletin - May 21, 2026
Hyperspectral Imaging Aims To Give Surgeons ‘Superhuman’ Insight
Emerging tech splits light into wavelengths beyond the human visible spectrum to give surgeons a better view of tissue
Medtech Insight - May 21, 2026
Emerging tech splits light into wavelengths beyond the human visible spectrum to give surgeons a better view of tissue
Medtech Insight - May 21, 2026
Behind China Deals: If The Trials Are More Fly, Then You Must Buy
Multinationals are developing new deal patterns with Chinese originators which enable them to tap into China’s strengths in early-stage clinical studies.
Scrip - May 21, 2026
Multinationals are developing new deal patterns with Chinese originators which enable them to tap into China’s strengths in early-stage clinical studies.
Scrip - May 21, 2026
AI, Robotics, AR And Next-Generation Tools Redefine Urology At AUA 2026
From AI-powered surgical navigation and force-feedback robotics to smart laser lithotripsy and Apple’s augmented reality, the 2026 AUA Annual Meeting showcased a technology-driven transformation across urologic subspecialties.
Medtech Insight - May 21, 2026
From AI-powered surgical navigation and force-feedback robotics to smart laser lithotripsy and Apple’s augmented reality, the 2026 AUA Annual Meeting showcased a technology-driven transformation across urologic subspecialties.
Medtech Insight - May 21, 2026
Jazz Digs In On Sleep And Epilepsy And Eyes What’s Next
Jazz used AAN 2026 to defend Epidiolex and Xywav with post-approval evidence, while signaling a shift toward a deeper rare-neuroscience platform beyond its two commercial brands.
In Vivo - May 21, 2026
Jazz used AAN 2026 to defend Epidiolex and Xywav with post-approval evidence, while signaling a shift toward a deeper rare-neuroscience platform beyond its two commercial brands.
In Vivo - May 21, 2026
Beyond the Blockbusters: The Next Wave of First-in-Class Oncology Mechanisms
In this article, the fourth and final instalment of the oncology therapeutic review series, In Vivo looks to the mechanisms competing to become the next frontier.
In Vivo - May 21, 2026
In this article, the fourth and final instalment of the oncology therapeutic review series, In Vivo looks to the mechanisms competing to become the next frontier.
In Vivo - May 21, 2026
Cost Impacts Change But Strategies To Respond Stay The Same For US Consumer Health Sector
In addition to reporting latest results, major OTC drug and supplement firms in April and May say their plans for responding to increasing oil and transportation costs and potential supply chain problems linked to the Middle East crisis are tested for effectiveness.
HBW Insight - May 21, 2026
In addition to reporting latest results, major OTC drug and supplement firms in April and May say their plans for responding to increasing oil and transportation costs and potential supply chain problems linked to the Middle East crisis are tested for effectiveness.
HBW Insight - May 21, 2026
Another Quarter, Another Acquisition For Prestige Consumer: Australian OTC Topical Firm LaCorium
Along with latest results, PCH follows April announcement of deal to acquire Breathe Right marketer Foundation Consumer for $1.045bn with May 13 announcement of agreement to acquire Australian OTC firm LaCorium Health International for around $150m.
HBW Insight - May 21, 2026
Along with latest results, PCH follows April announcement of deal to acquire Breathe Right marketer Foundation Consumer for $1.045bn with May 13 announcement of agreement to acquire Australian OTC firm LaCorium Health International for around $150m.
HBW Insight - May 21, 2026
Novartis On The Future Of CV In A World Of GLP-1s
CV, renal and metabolic R&D leaders Ruchira Glaser and Shaun Coughlin talked to Scrip about investments and catalysts in the therapeutic area.
Scrip - May 21, 2026
CV, renal and metabolic R&D leaders Ruchira Glaser and Shaun Coughlin talked to Scrip about investments and catalysts in the therapeutic area.
Scrip - May 21, 2026
Executives On The Move: Six CMOs And Four CFOs Among This Week’s Changes
Recent moves in the industry include changes at the top at Achieve Life Sciences, AstronauTx and IMMEDIATE Therapeutics, plus Johnson & Johnson gets a new Human Resources head in China.
Scrip - May 21, 2026
Recent moves in the industry include changes at the top at Achieve Life Sciences, AstronauTx and IMMEDIATE Therapeutics, plus Johnson & Johnson gets a new Human Resources head in China.
Scrip - May 21, 2026
BioMarin Looks To Expand Voxzogo Franchise With Positive Hypochondroplasia Data
Positive Phase III hypochondroplasia data could help BioMarin expand the Voxzogo franchise beyond achondroplasia as competition in skeletal dysplasias intensifies.
Scrip - May 21, 2026
Positive Phase III hypochondroplasia data could help BioMarin expand the Voxzogo franchise beyond achondroplasia as competition in skeletal dysplasias intensifies.
Scrip - May 21, 2026
Lilly Keeps Building Genetic Medicines Capabilities With $202m Engage Bio Buyout
Acquisition of the biotech and its non-viral DNA delivery technology adds to a string of bets across next-generation approaches in gene-based therapies.
Scrip - May 21, 2026
Acquisition of the biotech and its non-viral DNA delivery technology adds to a string of bets across next-generation approaches in gene-based therapies.
Scrip - May 21, 2026
Behind China Deals: If The Trials Are More Fly, Then You Must Buy
Multinationals are developing new deal patterns with Chinese originators which enable them to tap into China’s strengths in early-stage clinical studies.
Scrip - May 21, 2026
Multinationals are developing new deal patterns with Chinese originators which enable them to tap into China’s strengths in early-stage clinical studies.
Scrip - May 21, 2026
Health Organizations Rebuke Kennedy For Firing USPSTF Leadership
Several public health organizations are voicing concern over the firing of two top leaders of the US Preventive Services Task Force by HHS Secretary Robert F. Kennedy Jr. Critics say the removal of John Wong and Esa Davis erodes trust in the healthcare system and threatens public health.
Medtech Insight - May 21, 2026
Several public health organizations are voicing concern over the firing of two top leaders of the US Preventive Services Task Force by HHS Secretary Robert F. Kennedy Jr. Critics say the removal of John Wong and Esa Davis erodes trust in the healthcare system and threatens public health.
Medtech Insight - May 21, 2026
Execs On The Move: May 11–15, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - May 21, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - May 21, 2026
GHO, CBC Combine In $21bn Deal To Form Healthcare Investment Behemoth
The pact will combine the financial firms’ complementary strengths across Asia-Pacific, North America and Europe, creating an investment manager with more than $21bn in assets.
Medtech Insight - May 21, 2026
The pact will combine the financial firms’ complementary strengths across Asia-Pacific, North America and Europe, creating an investment manager with more than $21bn in assets.
Medtech Insight - May 21, 2026
Medtech On The Battlefield: Aristeia Takes Mechanical Tourniquet To Ukraine
The Norwegian start-up found itself in the war effort when the Ukrainian government ordered hundreds of its one-handed pull-cord tourniquets.
Medtech Insight - May 21, 2026
The Norwegian start-up found itself in the war effort when the Ukrainian government ordered hundreds of its one-handed pull-cord tourniquets.
Medtech Insight - May 21, 2026
Boston Scientific Doubles Down On Cardiac M&A As Pacemaker Recall Escalates
Four deaths, 2,557 serious injuries and 1.4 million devices later, the company is betting a software upgrade — and a wave of cardiac acquisitions — can contain the damage.
Medtech Insight - May 21, 2026
Four deaths, 2,557 serious injuries and 1.4 million devices later, the company is betting a software upgrade — and a wave of cardiac acquisitions — can contain the damage.
Medtech Insight - May 21, 2026
The Call At MedTech Forum 2026: Bring The Medtech Innovation Launch Pad Back To Europe
MedTech Europe CEO Oliver Bisazza set out his hopes and aims for EU industry and markets during the MedTech Forum 2026 against a backdrop of cautious optimism in regulatory and strategy circles now the MDR/IVDR revision is getting EU co-legislator attention. Elsewhere, there remains work to do.
Medtech Insight - May 21, 2026
MedTech Europe CEO Oliver Bisazza set out his hopes and aims for EU industry and markets during the MedTech Forum 2026 against a backdrop of cautious optimism in regulatory and strategy circles now the MDR/IVDR revision is getting EU co-legislator attention. Elsewhere, there remains work to do.
Medtech Insight - May 21, 2026
Hyperspectral Imaging Aims To Give Surgeons ‘Superhuman’ Insight
Emerging tech splits light into wavelengths beyond the human visible spectrum to give surgeons a better view of tissue
Medtech Insight - May 21, 2026
Emerging tech splits light into wavelengths beyond the human visible spectrum to give surgeons a better view of tissue
Medtech Insight - May 21, 2026
AI, Robotics, AR And Next-Generation Tools Redefine Urology At AUA 2026
From AI-powered surgical navigation and force-feedback robotics to smart laser lithotripsy and Apple’s augmented reality, the 2026 AUA Annual Meeting showcased a technology-driven transformation across urologic subspecialties.
Medtech Insight - May 21, 2026
From AI-powered surgical navigation and force-feedback robotics to smart laser lithotripsy and Apple’s augmented reality, the 2026 AUA Annual Meeting showcased a technology-driven transformation across urologic subspecialties.
Medtech Insight - May 21, 2026
Nestlé And Dr Reddy’s Launch Supplement For India’s GLP-1 Users
Indian users of GLP-1 therapies for weight loss can now purchase a supplement developed by Nestle and Dr Reddy's to support their nutritional requirements.
HBW Insight - May 21, 2026
Indian users of GLP-1 therapies for weight loss can now purchase a supplement developed by Nestle and Dr Reddy's to support their nutritional requirements.
HBW Insight - May 21, 2026
Health Literacy And Pharmacy Key To Improving Men’s Self-Care
A report from Global Action on Men's Health identifies health literacy and pharmacy as key levers for improving men's self-care, with implications for companies marketing OTC and consumer health products to men.
HBW Insight - May 21, 2026
A report from Global Action on Men's Health identifies health literacy and pharmacy as key levers for improving men's self-care, with implications for companies marketing OTC and consumer health products to men.
HBW Insight - May 21, 2026
Cost Impacts Change But Strategies To Respond Stay The Same For US Consumer Health Sector
In addition to reporting latest results, major OTC drug and supplement firms in April and May say their plans for responding to increasing oil and transportation costs and potential supply chain problems linked to the Middle East crisis are tested for effectiveness.
HBW Insight - May 21, 2026
In addition to reporting latest results, major OTC drug and supplement firms in April and May say their plans for responding to increasing oil and transportation costs and potential supply chain problems linked to the Middle East crisis are tested for effectiveness.
HBW Insight - May 21, 2026
Another Quarter, Another Acquisition For Prestige Consumer: Australian OTC Topical Firm LaCorium
Along with latest results, PCH follows April announcement of deal to acquire Breathe Right marketer Foundation Consumer for $1.045bn with May 13 announcement of agreement to acquire Australian OTC firm LaCorium Health International for around $150m.
HBW Insight - May 21, 2026
Along with latest results, PCH follows April announcement of deal to acquire Breathe Right marketer Foundation Consumer for $1.045bn with May 13 announcement of agreement to acquire Australian OTC firm LaCorium Health International for around $150m.
HBW Insight - May 21, 2026
Dr Reddy’s Adds Oral Tablets To Indian Semaglutide Offering
Dr Reddy’s has made good on recent promises to introduce its oral semaglutide generic in India.
Generics Bulletin - May 21, 2026
Dr Reddy’s has made good on recent promises to introduce its oral semaglutide generic in India.
Generics Bulletin - May 21, 2026
Strides Tempers US FY28 Guidance As Controlled Substances Face Quota Hurdle
Strides' US controlled substances portfolio is taking time to scale, but is set to deliver in FY29. Meanwhile, a FY28 US revenue guidance of $375m-$400m has been cut from $400m earlier, though an attempt to meet the target is on.
Generics Bulletin - May 21, 2026
Strides' US controlled substances portfolio is taking time to scale, but is set to deliver in FY29. Meanwhile, a FY28 US revenue guidance of $375m-$400m has been cut from $400m earlier, though an attempt to meet the target is on.
Generics Bulletin - May 21, 2026
Apixaban Tops Two Tables As UK Rises Persist In April
UK generics price rises continued in April, with apixaban rivals to Eliquis topping our Biggest Risers table while also reflecting the steepest increase among our Recent Launches.
Generics Bulletin - May 21, 2026
UK generics price rises continued in April, with apixaban rivals to Eliquis topping our Biggest Risers table while also reflecting the steepest increase among our Recent Launches.
Generics Bulletin - May 21, 2026
OneSource Adds US To Its Semaglutide Ambitions, Plans Capacity Hikes
OneSource has added the US to its geographic expansion plans for GLP-1 semaglutide and after a strong showing in India by its generics partners, it is hiking capacity for its drug-device combinations.
Generics Bulletin - May 21, 2026
OneSource has added the US to its geographic expansion plans for GLP-1 semaglutide and after a strong showing in India by its generics partners, it is hiking capacity for its drug-device combinations.
Generics Bulletin - May 21, 2026
Meloxicam Could Be Viatris’ Late Christmas Present
Viatris has secured a 27 December 2026 PDUFA date for fast-acting meloxicam, setting up a key US value-added medicines opportunity as it targets non-opioid acute pain and higher-margin growth.
Generics Bulletin - May 21, 2026
Viatris has secured a 27 December 2026 PDUFA date for fast-acting meloxicam, setting up a key US value-added medicines opportunity as it targets non-opioid acute pain and higher-margin growth.
Generics Bulletin - May 21, 2026
Gedeon Richter Wants More On GLP-1s
Hungarian player Gedeon Richter is deepening its GLP-1 push with multiple co-development talks, as its General Medicines generics unit works through a difficult first quarter.
Generics Bulletin - May 21, 2026
Hungarian player Gedeon Richter is deepening its GLP-1 push with multiple co-development talks, as its General Medicines generics unit works through a difficult first quarter.
Generics Bulletin - May 21, 2026
The Wonders Of The Microbiome Approach According To Freya Biosciences
Colleen Acosta, CEO and co-founder of Freya Biosciences, focuses on the success of developing microbial immunotherapies, and why industry must direct more attention to the space of women’s healthcare.
In Vivo - May 21, 2026
Colleen Acosta, CEO and co-founder of Freya Biosciences, focuses on the success of developing microbial immunotherapies, and why industry must direct more attention to the space of women’s healthcare.
In Vivo - May 21, 2026
MedTech Forum 2026: Global Trade Is No Longer Just A Question Of Economics
In 2026, the heavy hand of geopolitics, industrial policy, economic security and resilience has dictated the pace – or even the fact of – global trade in medtech, said MedTech Europe’s Diana Kanecka on a panel at the MedTech Forum 2026.
In Vivo - May 21, 2026
In 2026, the heavy hand of geopolitics, industrial policy, economic security and resilience has dictated the pace – or even the fact of – global trade in medtech, said MedTech Europe’s Diana Kanecka on a panel at the MedTech Forum 2026.
In Vivo - May 21, 2026
Jazz Digs In On Sleep And Epilepsy And Eyes What’s Next
Jazz used AAN 2026 to defend Epidiolex and Xywav with post-approval evidence, while signaling a shift toward a deeper rare-neuroscience platform beyond its two commercial brands.
In Vivo - May 21, 2026
Jazz used AAN 2026 to defend Epidiolex and Xywav with post-approval evidence, while signaling a shift toward a deeper rare-neuroscience platform beyond its two commercial brands.
In Vivo - May 21, 2026
Beyond the Blockbusters: The Next Wave of First-in-Class Oncology Mechanisms
In this article, the fourth and final instalment of the oncology therapeutic review series, In Vivo looks to the mechanisms competing to become the next frontier.
In Vivo - May 21, 2026
In this article, the fourth and final instalment of the oncology therapeutic review series, In Vivo looks to the mechanisms competing to become the next frontier.
In Vivo - May 21, 2026